An old enzyme for current needs: Adenosine deaminase and a dendritic cell vaccine for HIV

Immunology and Cell Biology

Volumn 90, Issue 6, 2012, Pages 594-600

  Martinez Navio, Jose M ^a   Climent, Nuria ^a   Gallart, Teresa ^a   Lluis, Carme ^a   Franco, Rafael ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ADA; adjuvant; HIV; memory cell; Th1; vaccine

Indexed keywords

ADENOSINE DEAMINASE; ANTIGEN; DENDRITIC CELL VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADJUVANT THERAPY; ARTICLE; CELLULAR IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNITY; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSTIMULATION; IN VITRO STUDY; INFECTION PREVENTION; MEMORY T LYMPHOCYTE; TH1 CELL;

ADENOSINE DEAMINASE; ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; DENDRITIC CELLS; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; VACCINATION;

EID: 84863724041     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.81     Document Type: Article

References (70)

1. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update, 2009 Available from: http://data.unaids.org/pub/Report/2009/jc1700-epi-update-2009- en.pdf.
2. Kamali A. What is new in HIV/AIDS research in developing countries? Trop Med Int Health 2010; 15: 975-980.
3. Watkins DI. HIV vaccine development. Top HIV Med 2010; 18: 35-36.
4. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323: 1304-1307.
5. Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F, Chun TW et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 2010; 329: 174-180.
6. Yang OO. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. AIDS 2008; 22: 325-331.
7. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205: 7-12.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220.
9. Benmira S, Bhattacharya V, Schmid ML. An effective HIV vaccine: a combination of humoral and cellular immunity? Curr HIV Res 2010; 8: 441-449.
10. Autran B, Carcelain G, Combadiere B, Debre P. Therapeutic vaccines for chronic infections. Science 2004; 305: 205-208.
11. Garcia F, Climent N, Assoumou L, Gil C, Gonzalez N, Alcami J et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011; 203: 473-478.
12. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10: 1359-1365.
13. Garcia F, Lejeune M, Climent N, Gil C, Alcami J, Morente V et al. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005; 191: 1680-1685.
14. Rinaldo CR. Dendritic cell-based human immunodeficiency virus vaccine. J InternMed 2009; 265: 138-158.
15. Oshiro TM, de Almeida A, da Silva Duarte AJ. Dendritic cell immunotherapy for HIV infection: from theory to reality. Immunotherapy 2009; 1: 1039-1051.
16. Van Gulck E, Van Tendeloo VF, Berneman ZN, Vanham G. Role of dendritic cells in HIVimmunotherapy. Curr HIV Res 2010; 8: 310-322.
17. Morrow MP, Weiner DB. Cytokines as adjuvants for improving anti-HIV responses. AIDS 2008; 22: 333-338.
18. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010; 22: 411-416.
19. Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol 2005; 35: 25-30.
20. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood 2009; 114: 3524-3532.
21. Franco R, Pacheco R, Gatell JM, Gallart T, Lluis C. Enzymatic and extraenzymatic role of adenosine deaminase 1 in T-cell-dendritic cell contacts and in alterations of the immune function. Crit Rev Immunol 2007; 27: 495-509.
22. Pacheco R, Lluis C, Franco R. Role of CD26-adenosine deaminase interaction in the T cell-mediated immunity. Inmunolog?́a 2005; 24: 235-245.
23. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 2010; 285: 7176-7186.
24. Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A et al. Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol 2007; 179: 1884-1892.
25. Pacheco R, Martinez-Navio JM, Lejeune M, Climent N, Oliva H, Gatell JM et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci USA 2005; 102: 9583-9588.
26. Martinez-Navio JM, Casanova V, Pacheco R, Naval-Macabuhay I, Climent N, Garcia F et al. Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. J Leukoc Biol 2011; 89: 127-136.
27. Kalantri Y, Hemvani N, Chitnis DS. Evaluation of real-time polymerase chain reaction, interferon-gamma, adenosine deaminase, and immunoglobulin A for the efficient diagnosis of pleural tuberculosis. Int J Infect Dis 2011; 15: e226-e231.
28. Gakis C. Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role. Eur Respir J 1996; 9: 632-633.
29. Vanham G, Kestens L, De Meester I, Vingerhoets J, Penne G, Vanhoof G et al. Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J Acquir Immune Defic Syndr 1993; 6: 749-757.
30. Blazquez MV, Madueno JA, Gonzalez R, Jurado R, Bachovchin WW, Pena J et al. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J Immunol 1992; 149: 3073-3077.
31. De Paoli P, Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest 1997; 100: 2737-2743.
32. Martinez-Navio JM, Climent N, Pacheco R, Garcia F, Plana M, Nomdedeu M et al. Immunological dysfunction in HIV-1-infected individuals caused by impairment of adenosine deaminase-induced costimulation of T-cell activation. Immunology 2009; 128: 393-404.
33. Valenzuela A, Blanco J, Callebaut C, Jacotot E, Lluis C, Hovanessian AG et al. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles. J Immunol 1997; 158: 3721-3729.
34. Murray JL, Loftin KC, Munn CG, Reuben JM, Mansell PW, Hersh EM. Elevated adenosine deaminase and purine nucleoside phosphorylase activity in peripheral blood null lymphocytes from patients with acquired immune deficiency syndrome. Blood 1985; 65: 1318-1324.
35. Delia S, Mastroianni CM, Massetti AP, Turbessi G, Cirelli A, Catania S et al. Adenosine deaminase activity and acquired immunodeficiency syndrome (AIDS). Clin Chem 1987; 33: 1675.
36. Tsuboi I, Sagawa K, Shichijo S, Yokoyama MM, Ou DW, Wiederhold MD. Adenosine deaminase isoenzyme levels in patients with human T-cell lymphotropic virus type 1 and human immunodeficiency virus type 1 infections. Clin Diagn Lab Immunol 1995; 2: 626-630.
37. Niedzwicki JG, Mayer KH, Abushanab E, Abernethy DR. Plasma adenosine deaminase2 is a marker for human immunodeficiency virus-1 seroconversion. Am J Hematol 1991; 37: 152-155.
38. Cowan MJ, Brady RO, Widder KJ. Elevated erythrocyte adenosine deaminase activity in patients with acquired immunodeficiency syndrome. Proc Natl Acad Sci USA 1986; 83: 1089-1091.
39. Climent N, Martinez-Navio JM, Gil C, Garcia F, Rovira C, Hurtado C et al. Adenosine deaminase enhances T-cell response elicited by dendritic cells loaded with inactivated HIV. Immunol Cell Biol 2009; 87: 634-639.
40. Connolly NC, Riddler SA, Rinaldo CR. Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches. AIDS Rev 2005; 7: 168-180.
41. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001; 98: 3006-3015.
42. Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ectoadenosine deaminase in lymphocytes. Immunol Rev 1998; 161: 27-42.
43. Schulze Zur Wiesch J, Thomssen A, Hartjen P, Toth I, Lehmann C, Meyer-Olson D et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 2011; 85: 1287-1297.
44. Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kok A et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog 2011; 7: e1002110.
45. Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 2009; 3: 349-358.
46. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 2004; 202: 266-274.
47. Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL. TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994; 8: 757-762.
48. Moore A, McCarthy L, Mills KH. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 1999; 17: 2517-2527.
49. ADAGENs Pegademase Bovine Injection-product information Available from: http://www.adagen.com/pdf/AdagenPI-May2010.pdf, http://www.sigmatau.com/ products/ AdagenPI-May2010.pdf.
50. ADAGENs Pegademase Bovine Injection-FDA information Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/019818s042lbl.pdf.
51. Aran JM, Colomer D, Matutes E, Vives-Corrons JL, Franco R. Presence of adenosine deaminase on the surface of mononuclear blood cells: immunochemical localization using light and electron microscopy. J Histochem Cytochem 1991; 39: 1001-1008.
52. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23: 1-21.
53. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830-1835.
54. Li D, Chen J, Jia M, Hong K, Ruan Y, Liang H et al. Loss of balance between T helper type 17 and regulatory T cells in chronic human immunodeficiency virus infection. Clin Exp Immunol 2011; 165: 363-371.
55. Whiteside TL, Piazza P, Reiter A, Stanson J, Connolly NC, Rinaldo Jr. CR et al. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2009; 16: 233-240.
56. Climent N, Guerra S, Garcia F, Rovira C, Miralles L, Gomez CE et al. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8 T cell responses in HIV-1-infected individuals. PLoS One 2011; 6: e19644.
57. Engelmayer J, Larsson M, Lee A, Lee M, Cox WI, Steinman RM et al. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol 2001; 75: 2142-2153.
58. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006; 24: 7124-7128.
59. Robertson SJ, Hasenkrug KJ. The role of virus-induced regulatory T cells in immunopathology. Springer Semin Immunopathol 2006; 28: 51-62.
60. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008; 7: 458-462.
61. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 2006; 116: 1935-1945.
62. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007; 19: 362-371.
63. Oukka M. Th17 cells in immunity and autoimmunity. Ann Rheum Dis 2008; 67(Suppl 3): iii26-iii29.
64. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8: 247-258.
65. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009; 6: 1-16.
66. Garcia F, Routy JP. Challenges in dendritic cells-based therapeutic vaccination in HIV infection-workshop in dendritic cell-based vaccine clinical trials in HIV. Vaccine 2011; 29: 6454-6463.
67. Porichis F, Kaufmann DE. HIV-specific CD4T cells and immune control of viral replication. Curr Opin HIV AIDS 2011; 6: 174-180.
68. Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ et al. HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T cell function. J Virol 2011; 85: 733-741.
69. Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003; 9: 27-32.
70. Gil C, Climent N, Garcia F, Hurtado C, Nieto-Marquez S, Leon A et al. Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines. Vaccine 2011; 29: 5711-5724.